Clinical Trial: Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM): a Single Arm Phase II Study

U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07237399) titled 'Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM): a Single Arm Phase II Study' on Nov. 14.

Brief Summary: The TA-P-OLIM Study (Percutaneous Thermo-Ablation of Prostate Cancer OligoMetastasis) is a prospective, interventional phase II study designed to evaluate the feasibility, efficacy, and safety of percutaneous thermal ablation (TA) as a metastasis-directed therapy (MDT) for patients with oligometastatic prostate cancer. So far, these metastases have been locally treated with stereotactic body radiation therapy (SBRT) or surgical resection.

Percutaneous TA is a minimally invasive tec...